All the news Showing 10 of 204 articles from: Finance, funding & health economicsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Washington takes 'Netflix' hep C drug pricing further with winner-take-all bidding Fierce Pharma / 29 January 2019 Needle and syringe programs cost-effectively prevent hepatitis C transmission Eurekalert Medicine & Health / 29 January 2019 Hepatitis C Drugs in 2019: Price Drops and Generic Pipeline in Place Hepatitis Central / 16 January 2019 Louisiana adopts ‘Netflix’ model to pay for hepatitis C drugs Washington Post / 13 January 2019 Bulgarian Harm Reduction Drown in Bureaucracy: Interview with Yuliya Georgieva Drug Reporter / 07 December 2018 When we find a cure, price it like Netflix to ensure access The Hill / 13 August 2018 Merck To Steeply Cut Price of Hepatitis C Drug Zepatier Managed Care Magazine / 22 July 2018 Novel Medicaid Strategy Proposed to Increase Access to HCV Treatment Infectious Disease Advisor / 29 May 2018 Early treatment for hepatitis C would be highly cost-effective for Scotland Keith Alcorn / 16 April 2018 Early treatment for hepatitis C is highly cost-effective in Scotland when compared to treatment initiated at the stages of advanced fibrosis or cirrhosis, according to a cost-effectiveness analysis presented on ... Model shows hepatitis C treatment is cost-effective in Japan Liz Highleyman / 27 November 2017 Treatment of chronic hepatitis C with direct-acting antivirals (DAAs) can lead to substantial savings by preventing the development of liver failure and liver cancer, according to a mathematical modelling study presented at the ... ← Prev12345...21Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive